We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.59B
AUM Growth
-$417M
Cap. Flow
-$178M
Cap. Flow %
-6.89%
Top 10 Hldgs %
30.75%
Holding
151
New
30
Increased
31
Reduced
32
Closed
17

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$42M
2
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$38M
3
AAC
AAC Holdings
AAC
+$37.8M
4
GSK icon
GSK
GSK
+$37.7M
5
RGNX icon
Regenxbio
RGNX
+$34.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$132M
2
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$38M
3
INGN icon
Inogen
INGN
+$26.8M
4
AERI
Aerie Pharmaceuticals
AERI
+$25.4M
5
BSX icon
Boston Scientific
BSX
+$24.9M

Sector Composition

Rank Sector Weight
1 Healthcare 68.89%
2 Financials 4.77%
3 Technology 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$160M 6.2%
8,081,407
-4,178,468
-34% -$132M
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
$99.6M 3.85%
6,318,050
+545,000
+9% +$8.74M
GSK icon
3
GSK
GSK
$104B
$87.8M 3.4%
1,826,178
+724,800
+66% +$37.7M
AET
4
DELISTED
Aetna Inc
AET
$69.6M 2.69%
636,039
+266,300
+72% +$30.8M
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$66.4M 2.57%
4,072,809
– –
DYAX
6
DELISTED
DYAX CORPORATION
DYAX
$54.6M 2.11%
2,857,773
+374,266
+15% +$8.94M
VNDA icon
7
Vanda Pharmaceuticals
VNDA
$327M
$54M 2.09%
4,784,157
– –
DVA icon
8
DaVita
DVA
$15.2B
$51.8M 2%
716,000
+80,000
+13% +$6.2M
VTRS icon
9
Viatris
VTRS
$20.1B
$51.3M 1.99%
1,275,000
+404,000
+46% +$22.5M
ALPN
10
DELISTED
Alpine Immune Sciences Inc
ALPN
$48.4M 1.87%
933,103
– –
ARRY
11
DELISTED
Array Biopharma Inc
ARRY
$44.4M 1.72%
9,729,361
+200,000
+2% +$1.19M
ADPT
12
DELISTED
Adeptus Health Inc
ADPT
$44M 1.7%
545,328
+181,328
+50% +$18.7M
EHTH icon
13
eHealth
EHTH
$47.3M
$41.8M 1.62%
3,264,588
– –
BLUE
14
DELISTED
bluebird bio
BLUE
$41.3M 1.6%
37,288
+12,060
+48% +$22M
WBA
15
DELISTED
Walgreens Boots Alliance
WBA
$38.5M 1.49%
463,457
-185,044
-29% -$16.7M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$37.5M 1.45%
+890,620
New +$42M
CRL icon
17
Charles River Laboratories
CRL
$10.8B
$36.9M 1.43%
581,188
-30,248
-5% -$2.17M
GWPH
18
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$35.7M 1.38%
391,122
+29,169
+8% +$3.24M
AAC
19
DELISTED
AAC Holdings
AAC
$35.6M 1.38%
1,601,376
+1,298,349
+428% +$37.8M
TEVA icon
20
Teva Pharmaceuticals
TEVA
$37.3B
$34.7M 1.34%
615,000
-31,000
-5% -$2.01M
MCK icon
21
McKesson
MCK
$98.5B
$34.4M 1.33%
185,646
+49,646
+37% +$10.5M
UAM
22
DELISTED
Universal American Corp
UAM
$33.7M 1.3%
4,930,787
+521,084
+12% +$4.22M
INFI
23
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$33M 1.28%
3,910,721
+1,445,592
+59% +$13.3M
TEVA icon
24
CALL
Teva Pharmaceuticals
TEVA
$37.3B
$31.1M 1.2%
+550,000
New +$35.7M
RGNX icon
25
Regenxbio
RGNX
$511M
$29.4M 1.14%
+1,336,542
New +$34.1M
1
2 3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2015 Portfolio in Review

As of Q3 2015, Deerfield Management held 151 positions worth $2.59B, down 14% from $3B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Deerfield Management withdrew a net $178M in Q3 2015, closing 17 positions and reducing 32 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 71% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in Global Blood Therapeutics, Inc. worth $37.5M.

  • Deerfield Management's largest Q3 2015 buy was Global Blood Therapeutics, Inc.: 890,620 shares worth $37.5M.
  • Deerfield Management added most to AAC Holdings in Q3 2015, an estimated $37.8M increase.
  • Deerfield Management's biggest Q3 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $132M.
  • Deerfield Management fully exited Spark Therapeutics, Inc. Common Stock in Q3 2015, selling an estimated $38M.
  • Deerfield Management's ten largest holdings make up 31% of its $2.59B portfolio in Q3 2015.
  • Deerfield Management opened 30 new positions and closed 17 in Q3 2015.
  • Deerfield Management's portfolio value fell 14% quarter-over-quarter to $2.59B.

Based on Deerfield Management's 13F filing for Q3 2015, filed 16 Nov 2015.